The sequence-specific cleavage of RNA molecules through ribozyme targeting is particularly attractive since it allows the effective abrogation of protein expression. So far, however, use of enzymatically active RNA molecules (ribozymes) has, without chemical modification, been severely hampered by ribozyme instability and poor cellular uptake. In this paper, we present a method for protection and cellular delivery of ribozymes by complexation with a low molecular weight polyethylenimine (LMW-PEI). We show that LMW-PEI almost completely stabilizes ribozymes or any RNA against degradation in vitro. Upon their highly efficient cellular uptake, non-toxic LMW-PEI-complexed ribozymes display intracellular bioactivity already at low concentrations as demonstrated by down-regulation of two different genes in different cell lines. In vivo, LMW-PEI-complexed ribozymes were stabilized after intraperitoneal (i.p.) injections, showed prolonged circulation time and intact ribozymes were detected in the subcutaneous (s.c.) tumor mass 60 min after the injection. In addition, i.p. injections of LMW-PEI-complexed ribozymes targeted against the growth factor pleiotrophin (PTN) resulted in marked reduction of s.c. human melanoma tumor growth and of intratumoral PTN levels in a mouse xenograft model. Thus, this paper describes a novel method for exogenous delivery of any bioactive RNA ribozyme in vitro and in vivo without chemical modification.
Introduction
Since their discovery, [1] [2] [3] ribozymes have attracted special attention due to their unique catalytic activities in splicing or cleaving RNA molecules in a sequencespecific manner. Because this cleavage renders an mRNA molecule untranslatable and prone to rapid degradation by intracellular nucleases, ribozyme action abrogates protein expression in a highly specific and effective manner, and ribozymes, eg short hammerhead ribozymes, 4 represent a potentially formidable therapeutic agent to control expression of any gene of interest. However, the use of ribozymes as therapeutic agents involves several issues such as cellular delivery, uptake, and intracellular localization, as well as ribozyme stability, catalytic activity, and toxicity. The delivery of DNA-based ribozyme expression constructs by viral or non-viral vectors has been widely used in vitro and in vivo (eg Refs. 5-8, and reviewed in Ref. 9 ) but this approach is hindered by problems with cell specificity, efficacy or safety issues, especially in vivo. The alternative approach, exogenous ribozyme drug delivery, offers a direct way of ribozyme application which is not based on gene therapy. This requires, however, extensive chemical modifications of all-RNA ribozyme molecules due to their high instability in biological sera and their poor cellular uptake (see Refs. 9,10 for review). Despite considerable efforts, these problems have severely hampered the development of therapeutic ribozymes to date with only a few exceptions (see Refs. 11,12 for review). Clearly, a generally applicable, highly efficient and less expensive method of stabilization and cellular delivery of active ribozymes is lacking which would allow a much broader use of ribozymes, eg in proteomics-related and therapeutic applications.
Polyethylenimines (PEIs) are synthetic branched polymers with a high cationic charge density and a protonable amino group in every third position. 13, 14 Commercially available high molecular weight (HMW) PEIs (25-800 kDa) are able to deliver large DNA molecules such as 2.3 Mb yeast artificial chromosomes (Yaks) 15 as well as plasmids or small oligonucleotides 13, [16] [17] [18] into mammalian cells in vitro and in vivo. This function as a potent transfection reagent relies on the PEI's ability to condense and compact the carried DNA into complexes, which form small colloidal particles allowing efficient cellular uptake through endocytosis. Additionally, this tight condensation of the DNA molecules as well as the buffering capacity of PEI in certain cellular compartments like endosomes and lysosomes also protects DNA from degradation ('proton sponge hypothesis'). compared to commercially available PEIs. 21 In in vitro experiments, LMW-PEI displays significantly lower toxicity combined with high DNA transfection efficiency when compared to HMW-PEI. 22 In this paper, we present a method for protection and cellular delivery of chemically unmodified RNA molecules in general and ribozymes in particular. Using LMW-PEI, ribozymes are efficiently stabilized against degradation and transfected into mammalian cells in vitro. LMW-PEI-complexed ribozymes display intracellular bioactivity as shown by specific and efficient downregulation of mRNA levels of two different targeted gene products. In vivo, ribozyme bioactivity is demonstrated in a mouse xenograft model by reduction of target gene levels and of tumor growth through LMW-PEI/ribozyme targeting of the growth factor pleiotrophin (PTN). Thus, we have established a method which for the first time allows exogenous delivery of any bioactive all-RNA hammerhead ribozyme in vitro and in vivo without chemical modifications.
Results and discussion
Stabilization of RNA by LMW-PEI Previously, LMW-PEI has been shown to form interpolyelectrolyte complexes with DNA. 21 In a first set of experiments, we studied whether this complexation also works with RNA, and if these LMW-PEI-based complexes result in stabilization and protection of RNA against enzymatic degradation. Two different [ 32 P]-labelled RNAs (300 and 900 nt) were generated by in vitro transcription and, complexed or not complexed with LMW-PEI, assayed for degradation over a 2 h period under various conditions. As expected, incubation of an unmodified 900 nt RNA in 1% fetal calf serum (FCS) at 371C led to a complete loss of the RNA within minutes as indicated by the absence of the full-length RNA band (Figure 1a ). After complexation with LMW-PEI, however, the RNA was stable and completely protected against degradation (Figure 1a) . Similar results were obtained with smaller RNA molecules (300 nt) and with FCS concentrations up to 44% (not shown), indicating that the stabilization works over a broad range independent of RNA length and concentration of serum proteins. To test more specifically for stability against pure ribonuclease, unmodified versus complexed RNA was incubated with 20 ng/ml RNaseA at 371C. Again, uncomplexed RNA was degraded almost instantaneously while LMW-PEI complexation provided protection (Figure 1b) . We attribute the initial minor losses of RNA to the incomplete complexation of some RNA molecules since later a plateau of complete stabilization of intact RNA molecules was reached. Again, similar results were obtained with shorter (300 nt) RNA molecules (not shown).
Due to their potential in specific down-regulation of genes, hammerhead ribozymes represent attractive RNA target molecules for stabilization. However, because of their markedly smaller molecular mass, they sometimes display different physical properties compared to longer RNA molecules (eg in cell transfection with cationic lipids 10 ). To study their LMW-PEI-based stabilization, [ 32 P]-end-labelled ribozymes (37 nt) were complexed with LMW-PEI and tested for degradation under the same conditions as described above. Our experiments confirmed that LMW-PEI-complexed ribozymes are protected against 1% FCS (Figure 1c To monitor the cellular uptake and distribution of LMW-PEI/ribozyme complexes, LMW-PEI and ribozymes were labelled with green and red fluorophores, respectively, and transiently transfected into ME-180 ( Figure  2a-h ), SW-13 and 1205LU cells (not shown). Thirty minutes after transfection, confocal microscopy demonstrated that, in addition to uncomplexed LMW-PEI, LMW-PEI/ribozyme complexes were taken up into cells and were mainly located in vesicular structures as seen by a predominantly yellow fluorescence representing LMW-PEI and ribozymes in close proximity (Figure 2c and d). These vesicles were most likely endosomes or lysosomes, indicating an uptake via endocytosis as has been described for other polycation/nucleic acid complexes. 23, 24 In addition, some cells showed to a minor extent a more diffuse green and red fluorescence ( Figure  2d ), most likely due to free, separated LMW-PEI and ribozymes in the cytoplasm after bursting of the vesicular membranes. After 4 h this staining pattern was more prominent (Figure 2h ), indicating that, while still vesicular LMW-PEI/ribozyme complexes were present, more of the LMW-PEI/ribozyme complexes had been released from the vesicles and were evenly distributed throughout the cells. A plausible mechanism for this release of intact complexes is supported by the 'proton sponge hypothesis' 13, 14 which suggests bursting of lysosomes due to swelling of PEI below physiological pH. Interestingly, there seemed to be no significant difference in the distribution of the LMW-PEI/ribozyme complexes between the cytosol and the nuclear compartment (Figure 2g and h). As expected, variations between different cells in terms of appearance and signal intensities indicated variations in the time course of complex uptake and release.
Since these fluorescence microscopy studies could not address the question of release of RNA in its intact and functional form, additional transfection experiments with DNA and RNA were performed. While LMW-PEIcomplexed DNA was readily expressed in 1205LU or ME-180 cells (Figure 2i , black or gray bars, respectively) as shown by transfection of a luciferase reporter gene plasmid, no luciferase activity was detected when luciferase mRNA was used for transfection ( Figure 2i , left). Obviously, nucleic acids are released from the LMW-PEI complex at the site of transcription (ie in the nucleus), which is in agreement with earlier studies demonstrating gene delivery from the cytoplasm to the nucleus by cationic polymers such as PEI. 25 Interestingly, however, despite oligonucleotide localization also in the cytoplasm as shown above (Figure 2a-h ), the cells cannot use LMW-PEI-delivered mRNA directly for translation. In contrast, lipofectamine transfection resulted not only in high expression of luciferase DNA as expected, but also in some luciferase activity in mRNA-transfected 1205LU cells indicating some mRNA delivery to the site of translation (Figure 2i , right).
Ribozyme bioactivity in tumor cells in vitro
To assess bioactivity of LMW-PEI-complexed ribozymes, tumor cells were transiently transfected, and at different time points cellular content of the targeted mRNA was determined by Northern blotting. In previous experiments, the ribozymes selected had been shown to effectively down-regulate the expression of the targeted gene upon stable transfection of the ribozyme expression vector. Rz332-BP is directed against a fibroblast growth factor binding protein (FGF-BP) which in some cancers can serve as an angiogenic switch molecule, can be ratelimiting for tumor growth in vitro and in vivo, and has been shown to be highly expressed in different squamous cell carcinoma cell lines including ME-180 cervix carcinoma cells. 8 The target of the ribozyme Rz66-PTN is the growth factor PTN which in vitro and in vivo 
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26 ME-180 cells were transfected for 5 h with 1.0 mg (B70 pmol), 0.1 mg (B7 pmol) or no LMW-PEI-complexed ribozyme Rz332-BP, respectively, and thereafter kept in normal medium for the times indicated in Figure  3a . As before, no visible negative effects on cell growth or morphology were seen microscopically during the treatment. Northern blots probed for the targeted gene (FGF-BP) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as loading control revealed marked, up to 460% down-regulation of FGF-BP mRNA upon ribozyme treatment while no difference in FGF-BP mRNA levels was seen in the negative control (Figure 3a) . Interestingly, the maximum reduction of FGF-BP mRNA levels found here was almost identical to earlier studies which describe stable transfection of a ribozyme Rz332-BP expression vector in the same cell line, 8 indicating the high efficiency of the new method of LMW-PEI-complexed ribozyme delivery. Here, with both ribozyme concentrations used, maximum effects were observed between 12 and 24 h after start of the transfection with subsequent recovery of FGF-BP mRNA levels. The initial delay in FGF-BP mRNA down-regulation reflects LMW-PEI-complexed ribozyme uptake by the cells, intracellular ribozyme release, and ribozyme action with subsequent RNA degradation by intracellular ribonucleases. Likewise, since LMW-PEI-ribozyme transfection is transient and was discontinued already after 5 h, a decrease in ribozyme activity between 24 and 36 h occurred as expected. Interestingly, for reasons still to be elucidated the lower ribozyme concentration displayed higher bioactivity as compared to the higher amount although the ribozyme/LMW-PEI ratio was identical. This may offer the perspective of using even lower ribozyme amounts in vitro and in vivo.
When 1205LU melanoma cells were transfected with ribozyme Rz66-PTN, similar results were obtained. Here, only 0.1 mg (B7 pmol) ribozyme was used since higher Ribozymes and gene expression A Aigner et al amounts led to LMW-PEI concentrations toxic for 1205LU cells (not shown). As seen before, maximum efficacy of ribozymes was reached after B20 h. Ribozyme action resulted in more than 40% down-regulation of the targeted PTN-mRNA (Figure 3b ) which again was identical to earlier results after stable transfection of a ribozyme expression vector in the same cell line. 26 PTN levels of control cells transfected with Rz332-BP directed against FGF-BP, which is not expressed by the 1205LU cell line, remained unchanged indicating the specificity of the delivered ribozymes.
Previously, transient transfections with the ribozyme Rz66-PTN stabilized by extensive chemical modifications or with the ribozyme expression vector were found to exert no effect on PTN mRNA levels in 1205LU cells (Czubayko et al, unpublished data) . Here, for the first time, we describe an easy and efficient method of delivering active ribozymes by transient transfection in vitro. Hence, this allows the study of gene functions in vitro in cell culture without the time-consuming and sometimes problematic stable transfections, and also offers a new, highly efficient approach for proteomicsrelated projects.
In vivo stabilization, intratumoral uptake, and ribozyme action on xenografted tumors
The ultimate goal of ribozyme targeting is the development of strategies for therapeutic in vivo delivery of bioactive ribozymes. Since the LMW-PEI-based ribozyme complexation method described here combines stabilization of ribozymes also under serum conditions with high efficacy of cellular delivery, we tested ribozyme stabilization, intratumoral uptake, and bioactivity in an in vivo animal model.
In order to demonstrate that intact ribozymes can reach a subcutaneous tumor after i.p. injections, in vivo pharmacokinetic studies with [ 32 P]-end-labelled ribozymes were performed. 1205LU melanoma cell tumor xenografts were grown in both flanks of athymic nude mice until they reached a size of B0.5 cm 3 . Two animals each were then injected i.p. with a total of 2 Â 10 6 dpm of [ 32 P]-end-labelled ribozymes complexed with PEI as described or without complexation as a negative control. Tissues were removed 60 min after the injections, RNA was extracted, and Northern analysis was performed to detect intact ribozyme-RNA within the tissues. Figure 4 shows that intact full-length 37 nt ribozymes could be detected in the tumor tissues only when complexed with PEI but not without prior complexation. Intact ribozymes were detected in almost all tissues tested (data not shown), and as expected after an i.p. injection, high amounts were found in the liver and kidney (Figure 4 ; 7 PEI). We concluded from this experiment that LMW-PEI-complexed ribozymes are stabilized in the circulation in vivo and that intact ribozymes can reach a subcutaneous tumor mass after i.p. injection. In order to estimate the percentage of the i.p. ribozyme dose that reaches the tumor, a semi-quantitative distribution experiment was performed. The experimental setting was the same as described above with the exception that the tissues were weighed, immediately homogenized and the retained radioactivity was counted in a scintillation counter. Approximately 1% of the total dose of 2 Â 10 6 dpm/injection was found within the tumors, which is in accordance with an even systemic distribution since the tumor mass of B400 mg represents B2% of the total body weight (20 g) of the mouse (data not shown). Again, radioactivity was detected in almost all tissues, except for the brain, which demonstrates that PEI-ribozyme complexes cannot easily pass the bloodbrain barrier (data not shown). In contrast to the first set of experiments ( Figure 4) where we detected only fulllength intact ribozyme-RNA, in this distribution analysis we cannot rule out that in addition to intact ribozymes also small amounts of degraded [ 32 P]-labelled nucleotides contributed to the total radioactivity counted.
Next, we wanted to test if i.p. injections of PEIribozyme complexes were able to down-regulate intratumoral target gene expression, and if this treatment could inhibit s.c. tumor growth. 1205LU melanoma cell tumor xenografts were grown in both flanks of athymic nude mice, and the mice were treated with LMW-PEIcomplexed ribozymes Rz66-PTN or Rz332-BP, with the latter serving as a negative control since 1205LU cells do not provide a target mRNA for Rz332-BP. According to our in vitro experiments, a dose as low as 8 mg/injection (B0.4 mg/kg per injection) was used, which is well below the range of toxic side effects of antisense oligonucleotides or chemically stabilized ribozymes (toxic effects starting at B10 mg/kg 27 ). As described previously, 28 injected cells grew visible tumors within a few days. For precise evaluation of total tumor mass, tumors were excised at the end of the experiment. A 48% reduction of mean tumor volume upon Rz66-PTN treatment was observed indicating a growth inhibitory effect of the PTN-specific ribozyme in comparison to the negative control (Figure 5a) .
In a second experiment, by employing a slightly different treatment protocol with more frequent ribozyme applications (see Materials and methods for details), ribozyme treatment resulted in obvious differences concerning tumor integrity in comparison to the control treatment. While growth of tumors consisting of a solid tumor mass was observed in animals treated with the control ribozyme Rz332-BP, the tumors felt considerably softer and more fragile in the ribozyme Rz66-PTN group. Consistent with this observation, microscopic evaluation of hematoxylin/eosin-stained sections revealed in several cases larger gaps between tumor cells in Rz66-PTN-treated tumors, probably indicating early Figure 4 In vivo stabilization and tissue uptake of LMW-PEI-complexed ribozymes. 1205LU tumor xenografts were grown s.c. in athymic nude mice until they reached a size of B0.5 cm 3 . Total doses of 2 Â 10 6 dpm of [ 32 P]-end-labelled Rz66-PTN ribozyme complexed with LMW-PEI (+; N/ P ratio of 53.33) or without complexation as a negative control (À) were injected i.p. into two animals per group. Northern blotting analysis demonstrated 60 min after the i.p. injections of complexed ribozymes intact full-length 37 nt ribozyme-RNA in the tumors, as well as the liver and the kidney. In contrast without complexation, no intact ribozyme-RNA was detected in any tissue even when the blots were exposed to films for up to 4 days. The experiment was repeated once and representative examples are shown.
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A Aigner et al stages of edema formation (data not shown). Additionally, determination of intratumoral PTN levels by ELISA 29 showed a 450% down-regulation of PTN upon Rz66-PTN treatment as compared to the control ribozyme group (Figure 5b) indicating high ribozyme bioactivity.
Taken together, our findings in both experiments demonstrate marked ribozyme-mediated reduction of PTN expression and consecutive impairment of tumor growth and tumor integrity in vivo. This is particularly remarkable since in our experiments no chemical modification of ribozymes is required and total ribozyme amounts applied here are lower than amounts generally used in other in vivo studies with chemically modified ribozymes or antisense oligonucleotides. This approach offers an avenue for the development of highly efficient and safe agents with broad therapeutic ranges.
Materials and methods

Synthesis of LMW-PEI, preparation of LMW-PEI/RNA and LMW-PEI/DNA complexes
The LMW-PEI was synthesized and extensively characterized as described by von Harpe et al.
22
For complexation, 9 mg LMW-PEI was diluted in 8 ml bidistilled water, adjusted to pH 7.4, brought to 10 ml and sterile filtered (0.2 mm). The desired amounts of RNA or DNA and of polymer solution were each diluted to 250 ml with 150 mM NaCl pH 7.4 and vortexed. After 10 min at room temperature, the polymer solution was added to the RNA or DNA solution and the resulting mixture was vortexed again. LMW-PEI/DNA ratios are defined on the basis of LMW-PEI nitrogen (N) per DNA phosphate (P) and expressed as PEI/DNA (N/P) equivalents. Optimal N/P ratios for cell transfection, as determined before with a luciferase expression vector, were used between N/P¼53.33 (1205LU melanoma cells) and N/P¼66.66 (ME-180 cervix carcinoma cells, SW-13 adrenal carcinoma cells). The complexes were allowed to equilibrate for 10 min at room temperature before use.
Labelling of RNA and measurement of RNA stability 300 bp/900 bp RNAs were synthesized by in vitro transcription of DNA plasmids using the Riboprobe System-T 7 kit (Promega, Madison, WI, USA) according to the manufacturer's protocol. [ LMW-PEI-based cell transfections, luciferase assays and Northern blotting SW-13, ME-180 and 1205 LU cells were maintained in culture at 371C/5% CO 2 using Iscove's modified Dulbecco's medium (IMDM, PAA Laboratories, Cö lbe, Germany) supplemented with glutamine and 10% heatinactivated fetal bovine serum (FBS, PAA Laboratories). Prior to transfection, 200 000 cells/well were seeded in six-well plates and cultivated at 371C/5% CO 2 with standard growth medium for 1 day. For luciferase assays, Ribozymes and gene expression A Aigner et al amounts indicated in Figure 3 of LMW-PEI-complexed luciferase RNA (Promega, Madison, WI, USA) or LMW-PEI-complexed plasmid DNA (N/P¼53.33 for 1205LU melanoma cells, and N/P¼66.66 for ME-180 cervix carcinoma cells and SW-13 adrenal carcinoma cells) consisting of the luciferase gene cloned into the plasmid pRc-CMV (Invitrogen) were diluted in 500 ml standard growth medium/well and cells were incubated for 5 h before the medium was changed. Luciferase activity was determined after 6 h and after 24 h using the Luciferase Assay System from Promega (Madison, WI, USA) as described by the manufacturer. For ribozyme transfections, 1.0 or 0.1 mg of ribozymes complexed with LMW-PEI as described (N/P¼53.33 for 1205LU cells, and N/ P¼66.66 for ME-180 cells) was diluted in 1000 ml standard growth medium/well, and cells were incubated for 5 h. The medium was changed once after 5 h and cells were cultivated for the times indicated in Figure 3 prior to lysis with Trizol reagent (Sigma, Deisenhofen, Germany) and preparation of mRNA was according to the manufacturer's protocol. PTN Northern blotting was done as described previously 26 with B5 mg total RNA per lane. To correct for different loading among different lanes, blots were stripped and re-probed for GAPDH. Bands were quantified by PhosphoImager analysis or by scanning of autoradiographed films.
Confocal laser scanning microscopy SW-13, ME-180 and 1205 LU cells were cultivated for 24 h using standard medium in eight well chamber slides (50 000 cells/well), and then treated with the same N/P ratios as described above of complexes of 18 mg Oregon Green 488-labelled LMW-PEI which was prepared as described 30 and purified by ultrafiltration, and 2 mg 5 0 -rhodamine-labelled ribozyme (Genset-Oligos, Paris, France). After 30 min or 4 h, cells were washed with phosphate-buffered saline (PBS) and fixed with 3% paraformaldehyde in PBS for 20 min, washed again and incubated for an additional 20 min with 0.1 mg/ml DAPI (4 0 ,6-diamindino-2-phenylindole dihydrochloride, Molecular Probes, Leiden, The Netherlands). For confocal microscopy, a Zeiss Axiovert 100M microscope connected to a Zeiss LSM 510 scan module was used. Excitation wavelengths were 364 nm for DAPI (Enterprise UV laser), 488 nm for Oregon Green (argon laser) and 543 nm for rhodamine (helium-neon laser). Images were recorded in multitracking mode using long-pass filters of 385 nm for DAPI, 505 nm for Oregon Green and 560 nm for rhodamine, and for detection of very faint fluorescence the detector gain was adjusted for fine sensitivity.
Tumor xenografts, in vivo pharmacokinetics, intraperitoneal (i.p.) application of LMW-PEI-based ribozyme complexes, and tumor growth analysis For the tumor growth analysis 2 Â 10 6 1205LU melanoma cells per site were injected subcutaneously (s.c.) into the flanks of 15 athymic nude mice (female NCr nu/nu). After reaching a size of B2 Â 2 mm at day 3, the animals were randomly assigned to two groups. Eight animals of the treatment group were injected i.p. with 8 mg/injection LMW-PEI-complexed ribozyme Rz66-PTN (N/P ratio of 53.33) in 100 ml PBS every second day for 2 weeks, and seven animals of the control group were treated identically with Rz332-BP. Three days after the last injection, the animals were sacrificed, tumors removed and tumor size measured. The second experiment was identical except for an earlier treatment start at day 2 after cell injection and tumor removal already 5 h after the last treatment. For microscopic analysis, cryosections of frozen tumor samples were prepared and hematoxylin/eosin stained. For the determination of PTN levels, tumor samples were homogenized in 200 ml Tris-buffered saline/0.5% Tween-20, and after centrifugation, supernatants were diluted 1:10 in the same buffer. The PTN ELISA was performed as described previously 29 with recombinant PTN as standard, and total protein concentration was determined using the D c Protein Assay from Bio-Rad (Hercules, CA, USA). Values were tested for normal distribution and statistical significances were evaluated by Student's t-test.
For the pharmacokinetic studies, 2 Â 10 6 1205LU melanoma cells per site were injected s.c. into the flanks of four athymic nude mice (female NCr nu/nu) per experiment. After reaching a size of B0.5 cm 3 after 10-14 days, the animals were randomly assigned to two groups. The two animals of the treatment group were injected i.p. with 2 Â 10 6 dpm [ 32 P]-end-labelled ribozyme Rz66 complexed to LMW-PEI in 200 ml PBS. The two animals of the control group were injected i.p. with 2 Â 10 6 dpm [ 32 P]-end-labelled ribozyme Rz66 without complexation to LMW-PEI (N/P ratio of 53.33) in 200 ml PBS. Sixty minutes after the injections the animals were sacrificed, the tissues removed and immediately snapfrozen in liquid nitrogen. RNA extraction and Northern blot analysis were performed as described above. The blots were exposed to films for 4 days. For the semiquantitative distribution analysis, independent experiments were performed using the same experimental tumor growth setting as described above. Again, 60 min after the i.p. injections of 2 Â 10 6 [
32 P]-end-labelled ribozymes with or without prior complexation to LMW-PEI, the tissues were removed, weighed, and immediately homogenized in 500 ml PBS. Total radioactivity was quantitated in triplicates using a liquid scintillation counter (Beckman, LS 6000 IC, Fullerton, CA, USA) and calculated according to the weight of the sample.
